Another recent example is the semi-synthetic FXR agonist obeticholic acid, which has been shown to improve NASH after 72 weeks’ treatment in a randomized, controlled clinical trial [86]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.